| Autor: |
Oude Munnink, TH, Henstra, MJ, Segerink, LI, Movig, KLL, Brummelhuis‐Visser, P |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Apr2016, Vol. 99 Issue 4, p419-431, 13p |
| Abstrakt: |
Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability of mAb pharmacokinetics, summarizes exposure-response data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementing mAb-TDM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text